Citi Increases Merck’s Price Target to $95, Highlighting Strong Pipeline
Merck & Co., Inc. (NYSE: MRK) has received a positive outlook from Citi, which recently raised its price target for the pharmaceutical giant to $95 from $84. This adjustment, announced…